In a recent published report, Kenneth Research has updated the Global Influenza Treatment Market report for for 2024 till 2030. Report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In the view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to be regain 25% by the end of 2024- Positive Growth in the economic demand and supply.
U.S. Market recovers fast; In a release on May 4th 2024, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2024. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2024. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2024. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2024 till March 2024 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Global Influenza Treatment Market products.
Get a Sample PDF of report-https://www.kennethresearch.com/sample-request-10334448
According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 9.08% in 2001 to 9.84% in 2018. Additionally, the current health expenditure per capita (current US$) increased from USD 492.99 in 2001 to USD 1110.84 in 2018. Moreover, growing concern for deaths caused due to various diseases and the need for treatment that can lower the crude death rate, which in the year 2019 recorded close to 7% (per 1000 people), are also anticipated to drive the market growth during the forecast period.
Global influenza treatment market will reach $1,371.0 billion by 2030, growing by 3.8% annually over 2024-2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment across the globe.
Highlighted with 83 tables and 77 figures, this 156-page report “Global Influenza Treatment Market 2024-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2024 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
To Understand How Covid-19 Impact Is Covered in This Report – Get a Sample PDF of report Enquire before purchasing this report –https://www.kennethresearch.com/sample-request-10334448
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Region.
Based on Product Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oseltamivir Phosphate
• Baloxavir Marboxil
• Peramivir
• Zanamivir
• Other Drugs
Based on Influenza Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Influenza A
• Influenza B
• Influenza C
Based on Administration Route, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oral Administration
• Other Administration Routes
Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Retail Pharmacy
• Hospital Pharmacy
• Clinics
• Online Stores
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• RoW (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Enquire before purchasing this report:https://www.kennethresearch.com/sample-request-10334448
For More reports:
Asia Pacific Air Quality Control Systems Market
Europe Air Quality Control Systems Market
North America Air Quality Control Systems Market
Global Air Quality Control Systems Market
About Kenneth Research:
Being a multi-client market research database platform, Kenneth Research aims at providing reports that help various individuals and organizations including industry professionals, to identify the market trends and scope, which further helps in their decision-making process and form strategies after complete assessment of the market. The various industries catered by the company include healthcare & pharmaceuticals, energy & power and several others. Kenneth Research, a global market research reselling firm, also provides strategic business consultancy services at a global level. Further, it also offers a single platform for the best market research reports.
Contact Us
Name: Kenneth research
Email:[email protected]
Phone: +1 313 462 0609
